Rewritten HubSpot Module

Rooted in Science

It’s at the heart of all that we do.

Our deep bench of PhDs, MDs, PharmDs, and MPHs brings unmatched scientific expertise to your med comms. More than subject matter experts, they are strategic communication partners, who provide an invaluable insider’s perspective. Their experience and insights translate into stronger scientific strategies, more impactful communications, and more relevant education for your HCP communities.

Deep therapeutic expertise from head to toe.

80+ Disease States 20 Therapeutic Areas

120+ PhDs, MDs, and PharmDs

Our staff is on call for you.

VERTICAL EXPERTISE

Rooted in science and driven by data, we deliver today’s most relevant scientific insights through a fiercely creative lens—providing the high-touch service and value of an independent agency, but with the innovation, firepower and results of a major enterprise. All while providing the education and implementation of the current best practices for the pharmaceutical industry.

Promotional Medical Education

IMMERSIVE PROMOTIONAL MEDICAL EDUCATION ENGAGEMENT.

Brand awareness is great, but we believe it’s all about surrounding our clients’ target HCP audiences with rich engagements that move them from awareness to trial, and then adoption—quickly and effectively. We deliver core peer-to-peer content and tactics to meet the highest standards for quality, accuracy and medical rigor that delivers a lasting impression for all of our customers’ brands.

Medical Affairs

EXPERTLY DESIGNED FOR MEDICAL AFFAIRS ORGANIZATIONS.

Over the years, we’ve developed and designed our offering specifically for medical affairs organizations. Our clients should not have to settle for commercial offerings retrofitted into a scientific context. Instead, we provide customized professional services dedicated to understanding and meeting our clients’ specific perspectives and objectives. Our agency is uniquely positioned to provide today’s most relevant education to HCPs in ways that are sensitive to their workflows and distinct knowledge bases.

Branding + Advertising

DELIVERING BRAND RESONANCE ACROSS TODAY’S HCP CHANNELS.

Our mission is to generate sustainable market awareness with today’s modern HCP. Awareness that drives engagement, learning, and a thirst to explore the content that makes our clients’ breakthrough brands. We’ve spent more than three decades honing our channel dynamic methods of engaging healthcare-specific audiences. And we believe it’s safe to say we do it better than the others, hands down.

Scientific Visualization

ANIMATIONS, EXHIBIT EXPERIENCE, AI INNOVATION AND BEYOND

What happens when artists are scientists, too? The Real Chemistry Visualization team includes a deep bench of PhD and graduate-level science degree-holders specializing in scientific visualization, with a 20-year history of developing scientific animations, illustrations, data visualizations and interactive experiences.

Meeting Planning

A STELLAR MEETING BRINGS EVERYTHING TOGETHER.

Bulletproof strategy, solid budget, excellent venue, and of course, the right people. Our meeting and planning staff act as more than just a partner, they become an extension of our clients’ team. 100% of our staff have earned the Certified Meeting Professional designation, and we follow the Project Management Body of Knowledge Guide (PMBOK® Guide) in all that we do. More than that, we understand that organizations and the people within them are all unique and every meeting is different. That’s why we tailor our approach for our clients every time.

Over 25 unique product/indications and counting

A key focus for over a decade, our work in oncology spans more than 25 unique product/indication combinations and counting. The evolution of our experience mirrors the unparalleled innovations we have witnessed and supported in the last decade, from chemotherapy to the advent of immuno-oncology, bispecific antibodies and T-cell engagers, and antibody-drug conjugates.

We leverage our deep expertise to help our partners navigate complex challenges across their solid tumor and hematologic oncology portfolios. Fluent in the nuances around accelerated approval and orphan drug status, we have partnered in 15-plus launches to date. Understanding the plethora of unmet needs, complex treatment regimens and oncologists’ insights, we facilitate robust medical conversations that advance scientific knowledge across treatment teams to improve patient care.

Breast Cancer

We have been helping our clients navigate the dynamic hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) landscape since cyclin-dependent kinase (CDK) inhibitors first became standard of care in metastatic disease. We provided strategic support in bringing a major advancement in care to market in the adjuvant setting and now look forward to the next wave of innovation in oral selective estrogen receptor degraders (SERDs). Whether it’s oncologists or the allied care team, overall survival, or managing side effects to preserve quality of life, we are experts in meeting your audience where they are and covering the topics that are most important to them and your brand.

Colorectal Cancer

We are experts on colorectal cancer, thanks to our many years serving clients in the gastrointestinal cancer space. Over the course of a decade, we have provided support ranging from mid-life cycle strategy and content development to full launch executions for a variety of products. We have seen and been a part of major innovations in this treatment landscape, including a recent tumor agnostic launch of a precision therapy, which fills an unmet need for certain patients with metastatic colorectal cancer. These breakthroughs and the positive impact they have on patients are what drive us.

Lung Cancer

Over a decade ago, we entered the lung cancer space with an indication expansion launch for a standard-of-care product, which we continued to support throughout its life cycle. Since then, our lung cancer portfolio has grown significantly to include a variety of products across lines of therapy and patient populations, including several new product launches and indication expansions. Whether it’s systemic chemotherapy or first-in-class precision oncology, we have become trusted strategic partners for our clients as they navigate the ever-evolving lung cancer treatment landscape.

Leukemia/Lymphoma/Myeloma

Our strategic partnership in hematologic oncology began in 2018. It has since grown to support multiple innovative therapies across a wide range of hematologic cancers, including AML, CLL, DLBCL, FL, and MCL to name a few. We have worked closely with our clients to fill the large unmet needs that exist within this field. Our work includes supporting several accelerated approval launches within six months, with more on the horizon as the landscape continues to evolve and more therapeutic options become available to patients in need.

THERAPEUTIC AREA SPOTLIGHT: IMMUNOLOGY

Cultivating breakthrough success

For more than a decade, we have worked in the immunology space, supporting multiple blockbuster products across more than 10 individual disease states. During this time, we have witnessed tremendous innovation within the field, with multiple disease states moving from a single modality to more than four separate classes of treatment options. Serving as a strategic partner for more than 15 new product/indication launches, we have helped our clients provide patients with much-needed treatment options. As we look ahead to the next 10 years, we can’t wait to help bring future innovative treatments to market.

Plaque Psoriasis

We have supported several products, including blockbuster innovations, within the plaque psoriasis space. With each new development, we have helped our partners raise patient and HCP expectations on what is possible with therapy, above and beyond just PASI 75 and even PASI 90.

Rheumatoid Arthritis

Through our experience across multiple classes of therapeutics, including biologics and small molecules, we have witnessed the move from focusing solely on tender and swollen joint counts to a treat-to-target approach. Remission is now the ultimate goal, with an increased focus on patient-centric approaches.

Spondyloarthropathies

Since 2014, we have supported new product and indication launches, including biologics and small molecules, in psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis.

Inflammatory Bowel Disease

Since 2014, we’ve had a front-row seat to witness the flood of innovation that has significantly expanded the inflammatory bowel disease (IBD) landscape. From tumor necrosis factor (TNF) inhibitors to the most recent approvals targeting S1P, JAK, and IL-23, we’ve supported multiple products across adult and pediatric Crohn’s disease and ulcerative colitis.

THERAPEUTIC AREA SPOTLIGHT: NEUROLOGY/PSYCHIATRY

Supporting brands at the forefront of innovation

For more than two decades, we’ve educated and advocated within the neurology and psychiatry spaces, and we bring unprecedented expertise, passion, and commitment to every project and challenge.

We have supported numerous blockbuster brands in more than 13 distinct disease states, and we continue to partner with our clients who are at the forefront of innovation and therapeutic advances.

Psychiatric disorders

We have helped define and redefine the treatment paradigm in the mental health space by supporting new brands and new indications across a range of mental health conditions. The emergence of these new therapies has significantly improved the lives of millions of patients living with disorders like schizophrenia, major depressive disorder, bipolar disorder, and—with the most recent breakthrough—treating patients with agitation associated with dementia due to Alzheimer’s disease.

Alzheimer’s disease

For more than a decade, we’ve served as strategic and scientific partners in the fight against Alzheimer’s disease. Within this space, we’ve supported the launch of diagnostic imaging agents, as well as paradigm-changing, disease-modifying therapies for the earliest clinical stages. From developing disease state education across the entire spectrum of disease to technical specialty trainings that aid in diagnosis, our experts are deeply passionate about the science, the patients, the caregivers, and the HCPs in this space.

Migraine

We entered the migraine space in 2017, and we’ve been in the thick of the exciting advancements ever since. Our support for multiple products, including launches, encompasses therapies for acute migraine relief as well as migraine prevention. From differing mechanisms of action to different modes of administration, we have galvanized HCP adoption and advocacy across both neurology and primary care.

Parkinson’s disease

Supporting both in-market and investigational products, we’ve provided strategic partnership in the Parkinson’s disease space for many years. We have helped our clients navigate complex challenges around delivering effective treatments for Parkinson’s disease using novel delivery devices. Given the rapid advancements in therapy and modes of administration for Parkinson's disease, we are passionate in helping our clients address the large unmet need in this space to provide more tolerable and consistent relief for patients.

Therapeutic Areas of Expertise

OUR SCIENTIFIC EXPERIENCE RUNS DEEP

Like the healthcare space we’ve been a part of since 1994, our expertise is ever-evolving, as scientific innovations bring new opportunities to expand the depth and breadth of our support to our clients, their HCP customers, and their patients, whom we ultimately serve.

Cardiology

We’ve supported our partners through significant innovations for the treatment of the following cardiovascular disorders:

Heart failure with preserved ejection fraction (HFpEF)

• Heart failure with reduced ejection fraction (HFrEF)

• Atrial fibrillation (Afib)

Dermatology

Across the dermatological landscape, we’ve helped our clients bring powerful therapeutic solutions to market in the following areas:

Plaque psoriasis (PsO)

• Psoriatic arthritis (PsA)

• Atopic dermatitis (AD)

• Hidradenitis suppurativa (HS)

Endocrinology

We have deep experience helping our clients introduce novel therapies for the treatment of the following chronic conditions:

Diabetes

• Osteoporosis

Gastroenterology

We’ve been proud to assist our clients in their quest to bring innovative therapeutic options to patients with:

Adult and pediatric Crohn’s disease (CD) and ulcerative colitis (UC)

• Irritable bowel syndrome (IBS)

• Chronic idiopathic constipation

• Eosinophilic esophagitis (EE)

• Exocrine pancreatic insufficiency (EPI)

• Postoperative nausea and vomiting (PONV)

Hematology Oncology

We’ve remained laser-focused on helping our clients bring the benefits of precision medicine to life, as they have introduced biomarker-targeted therapies and other breakthrough treatments to many patients with the following blood cancers: Chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL)

• Acute myeloid leukemia/myelodysplastic syndrome (AML/MDS)

• Multiple myeloma (MM)

• Myelofibrosis (MF)

• Diffuse large B-cell lymphoma (DLBCL)

• Mantle cell lymphoma (MCL)

• Follicular lymphoma (FL)

Nephrology

Through experience, we’ve cultivated a strong background in developing compelling medical education programs for:

Autosomal dominant polycystic kidney disease (ADPKD)

Neurology

We have extensive experience across psychiatry, neurodegeneration, and pain that includes:

Agitation associated with dementia due to Alzheimer’s disease (AAD)

• Bipolar I disorder (BP-I)

• General anxiety disorder (GAD)

• Major depressive disorder (MDD)

• Schizophrenia (SZ)

• Post-traumatic stress disorder (PTSD)

• Alzheimer’s disease (AD)

• Huntington’s disease

• Parkinson’s disease (PD)

• Migraine

• Cluster headache

• Chronic pain syndromes

Nutrition

Providing food for thought and meaningful discussion, we’ve successfully supported our clients in the following areas:

Supportive care

• Infant/pediatric nutrition

• Food allergies

Ophthalmology

Bringing the major advances in this field into view, we’ve supported our clients as they’ve introduced innovative treatment solutions for:

Uveitis

• Presbyopia

• Open angle glaucoma (OAG)

• Age-related macular degeneration (AMD)

Pain management

We’ve shared the same determination as our clients to bring meaningful relief to patients in the following areas:

Osteoarthritis

• Chronic lower back pain (CLBP)

• Diabetic peripheral neuropathic pain (DPNP)

• Fibromyalgia (FM)

• Anesthesiology

Precision medicine

We’ve had the privilege to support our clients as they pave the way for more personalized treatments through innovations in:

Biomarkers

Pulmonology

We’ve partnered with our clients to bring clinically meaningful treatment options to patients with:

Chronic obstructive pulmonary disease (COPD)

• Cystic fibrosis (CF)

Radiology

We’ve helped our clients provide clinicians with critical training in:

Diagnostic imaging

Rare/Orphan Diseases

We’ve supported our clients’ work to deliver advances that have made a difference in the lives of patients with rare diseases, including:

Autosomal dominant Polycystic kidney disease (ADPKD)

• Cystic fibrosis

• Hemophilia

• Hereditary angioedema

• Huntington’s disease

• Thyroid eye disease

• Uveal melanoma

• Sjögren’s

• Behcet’s

• Spinocerebellar ataxia

• Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis

• Antiphospholipid syndrome

Rheumatology

As our clients seek to improve the lives of patients, we’ve been relentless in supporting their efforts around the following incapacitating conditions:

Rheumatoid arthritis (RA)

• Psoriatic arthritis (PsA)

• Ankylosing spondylitis (AS)

• Non-radiographic axial spondyloarthritis (NR-axSpA)

• Juvenile idiopathic arthritis (JIA)

Solid Tumor Oncology

As a witness to unprecedented breakthroughs in oncology, we’ve supported the advent of personalized medicine for patients with:

Head and neck cancer

• Metastatic uveal melanoma

• Breast cancer

• Non-small cell lung cancer (NSCLC)

• Gastroesophageal adenocarcinoma

• Gastric cancer

• Hepatocellular carcinoma

• Colorectal cancer

• Prostate cancer

• Bladder cancer

Urology

We’ve become specialists in supporting our clients’ solutions for the treatment of the following sensitive conditions:

Benign prostatic hyperplasia (BPH)

• Erectile dysfunction (ED)

• Nocturia

Virology

Our support for breakthrough therapies has helped our clients advance the fight against the following widespread viral infections:

COVID-19

• Human immunodeficiency virus (HIV)

• Hepatitis B (HBV)

• Hepatitis C (HBC)

• Human papillomavirus (HPV)

Women’s Health

Supporting important advances in women’s health, we have developed medical education initiatives that have addressed the following painful, often debilitating conditions:

Fibroids

• Endometriosis

• Preterm labor

• Preeclampsia

• Dyspareunia

• Hypoactive sexual desire dysfunction (HSDD)

Our Medical Leaders

Ujwal Pyati, PhD

Chief Medical Officer

Jason Gardner, PhD

SVP, Global Head of Medical

Sarah Wilson, PhD

SVP, US Medical